Choroidal Melanoma

Managing medium-sized choroidal melanoma with good visual acuity requires a personalized approach balancing tumor control and vision preservation. Current evidence-based treatment options include plaque brachytherapy, proton beam therapy, and stereotactic radiosurgery. Brachytherapy offers localized radiation delivery, while proton therapy and radiosurgery minimize radiation to surrounding healthy tissues. The choice depends on factors like tumor size, location, patient preferences, and access to specialized centers. Selecting the appropriate treatment necessitates a multidisciplinary team discussion involving ophthalmologists, oncologists, radiation therapists, and potentially medical physicists. Explore how different treatment modalities impact visual outcomes and quality of life to inform shared decision-making with the patient. Consider implementing a comprehensive follow-up protocol with regular ophthalmic examinations and imaging to monitor tumor response and manage potential complications such as radiation retinopathy or optic neuropathy.

Differentiating choroidal melanoma from a benign choroidal nevus is crucial for appropriate management. Key features on fundus examination suggestive of melanoma include thickness greater than 2mm, subretinal fluid, orange pigment (lipofuscin), and documented growth. Multimodal imaging such as ultrasound biomicroscopy (UBM), fundus autofluorescence (FAF), and optical coherence tomography (OCT) can provide further information on tumor characteristics and help assess risk. UBM can help determine tumor thickness and internal reflectivity. FAF can identify lipofuscin accumulation, and OCT can detect subretinal fluid and other related retinal changes. While these imaging modalities aid in risk stratification, biopsy is rarely indicated for diagnosis due to the potential risks of complications such as tumor seeding. Instead, close monitoring with serial imaging is generally preferred for suspicious nevi. However, in cases with high suspicion of melanoma despite inconclusive imaging, or in cases with atypical features, fine-needle aspiration biopsy (FNAB) may be considered after careful evaluation of the risks and benefits. Learn more about the specific characteristics of each imaging modality and their role in the diagnostic pathway for choroidal lesions.

Prognostic factors for uveal melanoma metastasis include tumor size, location, cytogenetic profile (monosomy 3, 8q gain), and extraocular extension. Larger tumors and those located in the ciliary body carry a higher risk of metastasis. Genetic analysis, particularly for monosomy 3, is increasingly important in predicting metastatic potential. Patients with monosomy 3 have a significantly higher risk of developing metastatic disease. These prognostic factors significantly influence treatment decisions and surveillance strategies. Patients with high-risk features may be considered for adjuvant therapy clinical trials and require more intensive surveillance with liver imaging and systemic examinations. While liver is the most common site of metastasis, other sites can be involved. Consider implementing a risk-stratified approach to surveillance, with closer follow-up for patients with high-risk features. Understanding these prognostic factors and their implications is crucial for individualized patient counseling and management. Explore how molecular profiling and emerging biomarkers may further refine prognostication and personalize therapeutic strategies for uveal melanoma.